Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus.
de Kruif
M D
MD
Limper
M
M
Hansen
H R
HR
de Ruiter
J
J
Spek
C A
CA
van Gorp
E C M
EC
ten Berge
I J
IJ
Rowshani
A T
AT
ten Cate
H
H
Meesters
E W
EW
D002097:C-Reactive Protein / Q000378:metabolism; D018592:Cross-Over Studies; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D011743:Pyrimidines / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*
D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein